Overview#
Goldman Sachs, a major U.S. investment bank, has pointed out a notable gap in the valuation of U.K. stocks. The bank describes the market as "under-loved" and "under-owned" by both local and international investors, even as global market sentiment stabilizes.
Deep Valuation Discounts#
In a recent report, analysts led by Sharon Bell indicated that U.K. equities are trading at about a 40% discount compared to U.S. stocks on a sector-neutral basis. This discount is considered "very deep" when looking at historical trends. When compared to European stocks, U.K. shares are still lagging, trading at a 15% to 20% discount.
The analysts attribute this ongoing undervaluation to a trend called "de-equitization," where U.K. pension and insurance funds have significantly reduced their investments in local stocks—from over 50% in the late 1990s to just 4% today. While the FTSE 100 index has benefited from strong performances in traditional sectors like energy and commodities, it has not experienced the rapid growth seen in technology-focused indices.
Attractive Yield Opportunities#
Despite the low domestic interest, Goldman Sachs argues that the U.K. market presents an appealing opportunity for yield-seeking investors. The FTSE 100 currently offers a dividend yield of around 4%, which is notably higher than the 1.5% yield from the S&P 500, making it an attractive option for those looking for income.
Corporate Actions and M&A Activity#
To counteract the lack of domestic enthusiasm, U.K. companies are increasingly engaging in share buybacks, reaching record levels in 2025. This strategy allows companies to return capital to shareholders while taking advantage of lower valuations. Additionally, the valuation gap has made U.K. firms attractive targets for foreign acquisitions. Recent increases in mergers and acquisitions, particularly from private equity and U.S. companies, indicate that international investors see value where local investors do not. Goldman Sachs suggests that while a quick recovery in valuations may be unlikely, the combination of high yields and potential acquisition premiums offers a favorable risk-reward scenario for patient investors.